What the company does
SD Biosensor makes in-vitro diagnostic (IVD) test kits and instruments, devices that analyse blood, urine, or other body samples outside the body to detect infectious diseases and chronic conditions.
Its products are used by hospitals, clinics, and public-health programmes, including international procurement bodies such as Global Fund and UNICEF. Listed on KOSPI, Korea's main stock exchange, the company operates a recurring-revenue model in which instruments placed at customer sites continuously consume its proprietary reagents and consumables.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$475.1M
- FY2024US$503.3M
- FY2025US$514.9M
Operating profit
- FY2023−US$179.8M
- FY2024−US$39.2M
- FY2025−US$58.7M
Net income
- FY2023−US$339.1M
- FY2024−US$71.1M
- FY2025−US$372M
Key ratios (FY2025)
Why it matters · Context, not a recommendation
The company holds regulatory clearances from WHO PQ, CE-IVD/IVDR, and FDA, which are required to access international public-procurement markets alongside commercial channels.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?